2017 Post-EASL Report

Share:

As chronic hepatitis C virus (HCV) drug development approaches the end-game following the launch of the first pan-genotypic regimen Epclusa ([sofosbuvir + velpatasvir]; Gilead), recent and upcoming advances in chronic hepatitis B virus (HBV) treatment emerged as an important focus of the International Liver Conference (ILC) 2017, the annual meeting of the European Association for the Study of the Liver (EASL), which took place in Amsterdam, the Netherlands, on 19–23 April 2017.

2017 Post-EASL Report summarizes several notable highlights and key abstracts from this year’s EASL conference.

Скачать (PDF, 1.86MB)

Source

Share: